BeiGene | A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

⟵ Back to Search Results

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Beigene Study ID

BGB-A317-26808-101

ClinicalTrials.gov ID

NCT05981703

China Drug Trials ID

CTR20240210

Sex: All

Age: 18 Years / N/A

No Study Documents

Locations

Sex: All

Age: 18 Years / N/A

No Study Documents